NCT04605887View on ClinicalTrials.gov

Angiotensin 1-7 as a Therapy in the Treatment of COVID-19

PHASE2UnknownINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

April 30, 2024

Conditions

COVID-19

Interventions

DRUG

Angiotensin 1-7

Ang 1-7 subcutaneously 500 mcg/kg /day

Trial Locations (1)

3525408

RECRUITING

Rambam Medical Center, Haifa

Sponsors

Collaborators (1)

Constant Therapeutics LLC

All Listed Sponsors

collaborator

Constant Therapeutics LLC

INDUSTRY

lead

Rambam Health Care Campus

OTHER

NCT04605887 - Angiotensin 1-7 as a Therapy in the Treatment of COVID-19 | Biotech Hunter | Biotech Hunter